NEW YORK, Feb. 22, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on AGN, CPRX, FLXN, and SUPN which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market today, WallStEquities.com scans Allergan PLC (NYSE: AGN), Catalyst Pharmaceuticals Inc. (NASDAQ:
On Wednesday, shares in Dublin, Ireland headquartered Allergan PLC recorded a trading volume of 2.69 million shares. The stock ended at $159.31, declining slightly by 0.80% from the last trading session. The Company's shares are trading below their 50-day moving average by 7.46%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 36.58.
On February 07th, 2018, research firm Leerink Partners reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $237 a share to $242 a share.
On February 09th, 2018, Allergan announced that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018, payable on March 28th, 2018, to shareholders of record at the close of business on February 28th, 2018. The Company also announced that its 2018 Annual General Meeting of Shareholders will be held on May 02nd, 2018 in Dublin, Ireland. Get the full research report on AGN for free by clicking below at: www.wallstequities.com/registration/?symbol=AGN
Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock finished yesterday's session 2.78% lower at $3.15 with a total trading volume of 544,099 shares. The Company's shares have gained 7.51% over the previous three months and 178.76% over the past year. The stock is trading above its 200-day moving average by 5.92%. Furthermore, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 34.84.
On February 12th, 2018, Catalyst Pharma (CPRX) announced the results of its recent Type C meeting with the US FDA. The minutes of the meeting received from the FDA reflect its advice to CPRX that the Company's proposed filing package will be sufficient for resubmission of a new drug application (NDA) for Firdapse® for LEMS. The Company currently anticipates resubmitting its NDA for Firdapse to the FDA by the end of Q1 2018. The free technical report on CPRX can be accessed at: www.wallstequities.com/registration/?symbol=CPRX
On Wednesday, shares in Burlington, Massachusetts headquartered Flexion Therapeutics Inc. jumped 4.24%, ending the day at $24.58. The stock recorded a trading volume of 1.25 million shares, which was above its three months average volume of 898,800 shares. The Company's shares have advanced 5.54% in the last month, 4.29% in the previous three months, and 25.03% over the past year. The stock is trading 1.07% and 7.38% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 55.44.
On February 02nd, 2018, Flexion Therapeutics announced a grant of inducement stock options to six new employees for an aggregate of 38,800 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an effective date of February 01st, 2018. The stock options have an exercise price of $22.31 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Sign up for free on Wall St. Equities and claim the latest report on FLXN at: www.wallstequities.com/registration/?symbol=FLXN
Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s shares ended the day 2.28% higher at $38.10 with a total trading volume of 408,901 shares. The stock has gained 0.26% over the previous three months and 47.39% over the past year. The Company's shares are trading 5.50% below their 50-day moving average. Additionally, shares of Supernus Pharma have an RSI of 45.63.
On February 12th, 2018, Supernus Pharma announced that the Company expects to report its Q4 and full-year 2017 financial results on February 27th, 2018, after 5:00 p.m. ET. Jack Khattar, President and CEO, and Greg Patrick, CFO, will host a conference call on February 28th, 2018, at 9:00 a.m. ET to present the results. See the free research coverage on SUPN at: www.wallstequities.com/registration/?symbol=SUPN
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-generic-drugs-stocks----allergan-catalyst-pharma-flexion-therapeutics-and-supernus-pharma-300602607.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Bronchopulmonary dysplasia or chronic lung disease of infancy is seen in premature and low birth ...
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...
If you want to stop breastfeeding, then here is your guide to doing it the right way. Find the ...View All